Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bayer
Biotech
ESMO: Exelixis' TKI reduces risk of death by 20%
The company believes the data for zanzalintinib validate its hopes of having another “franchise molecule” on its hands.
James Waldron
Oct 20, 2025 2:30am
Bayer picks Kumquat for $1.3B KRAS collaboration
Aug 12, 2025 6:29am
Bayer-allied NextRNA Therapeutics winds down operations
Aug 11, 2025 2:30pm
Bayer-owned BlueRock lays off 50 employees, shuts Cambridge labs
Jun 25, 2025 7:46am
Vividion secures clinical-stage WRN inhibitor from Roche
Jun 4, 2025 9:21am
BMS oncology head swings to Syndax—Chutes & Ladders
May 16, 2025 8:30am
